KR100532178B1 - 인간화 항-CD11a 항체 - Google Patents

인간화 항-CD11a 항체 Download PDF

Info

Publication number
KR100532178B1
KR100532178B1 KR10-1999-7004671A KR19997004671A KR100532178B1 KR 100532178 B1 KR100532178 B1 KR 100532178B1 KR 19997004671 A KR19997004671 A KR 19997004671A KR 100532178 B1 KR100532178 B1 KR 100532178B1
Authority
KR
South Korea
Prior art keywords
antibody
delete delete
cd11a
humanized anti
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR10-1999-7004671A
Other languages
English (en)
Korean (ko)
Other versions
KR20000069147A (ko
Inventor
파울라 엠. 자르듀
레오나르드 지. 프레스타
Original Assignee
제넨테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제넨테크, 인크. filed Critical 제넨테크, 인크.
Publication of KR20000069147A publication Critical patent/KR20000069147A/ko
Application granted granted Critical
Publication of KR100532178B1 publication Critical patent/KR100532178B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR10-1999-7004671A 1996-11-27 1997-10-20 인간화 항-CD11a 항체 Expired - Lifetime KR100532178B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75720596A 1996-11-27 1996-11-27
US08/757,205 1996-11-27
US8/757,205 1996-11-27
PCT/US1997/019041 WO1998023761A1 (en) 1996-11-27 1997-10-20 HUMANIZED ANTI-CD11a ANTIBODIES

Publications (2)

Publication Number Publication Date
KR20000069147A KR20000069147A (ko) 2000-11-25
KR100532178B1 true KR100532178B1 (ko) 2005-12-01

Family

ID=25046834

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-1999-7004671A Expired - Lifetime KR100532178B1 (ko) 1996-11-27 1997-10-20 인간화 항-CD11a 항체

Country Status (17)

Country Link
EP (2) EP1516629B1 (cg-RX-API-DMAC10.html)
JP (2) JP3778945B2 (cg-RX-API-DMAC10.html)
KR (1) KR100532178B1 (cg-RX-API-DMAC10.html)
AR (1) AR008919A1 (cg-RX-API-DMAC10.html)
AT (1) ATE267257T1 (cg-RX-API-DMAC10.html)
AU (1) AU731817C (cg-RX-API-DMAC10.html)
CA (1) CA2272842C (cg-RX-API-DMAC10.html)
DE (3) DE122004000047I2 (cg-RX-API-DMAC10.html)
DK (2) DK0941344T3 (cg-RX-API-DMAC10.html)
ES (1) ES2221045T3 (cg-RX-API-DMAC10.html)
FR (1) FR04C0028I2 (cg-RX-API-DMAC10.html)
IL (3) IL130143A0 (cg-RX-API-DMAC10.html)
LU (1) LU91122I2 (cg-RX-API-DMAC10.html)
NL (1) NL300163I2 (cg-RX-API-DMAC10.html)
PT (1) PT941344E (cg-RX-API-DMAC10.html)
WO (1) WO1998023761A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA979599B (cg-RX-API-DMAC10.html)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
SI1135498T1 (sl) 1998-11-18 2008-06-30 Genentech Inc Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
WO2000056363A1 (en) 1999-03-19 2000-09-28 Genentech, Inc. Treatment of lfa-1 associated disorders with increasing doses of lfa-1 antagonist
EP1237575B1 (en) * 1999-12-14 2008-08-06 Genentech, Inc. Tnf-alpha antagonist and lfa-1 antagonist for treating rheumatoid arthritis
US7560275B2 (en) 1999-12-30 2009-07-14 Vbi Technologies, L.L.C. Compositions and methods for generating skin
US7575921B2 (en) 1999-12-30 2009-08-18 Vbi Technologies, L.L.C. Spore-like cells and uses thereof
AU2001230920A1 (en) * 2000-01-14 2001-07-24 Genentech Inc. Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1
CA2417432C (en) * 2000-09-01 2010-11-02 The Center For Blood Research, Inc. Modified polypeptides stabilized in a desired conformation and methods for producing same
US20020151050A1 (en) 2000-10-30 2002-10-17 Vacanti Charles A. Isolation of spore-like cells from tissues exposed to extreme conditions
EP1472275B1 (en) 2002-02-05 2008-12-17 Genentech, Inc. Protein purification
SI1501369T1 (sl) 2002-04-26 2015-10-30 Genentech, Inc. Neafinitetno čiščenje proteinov
EP2277532A1 (en) 2002-09-11 2011-01-26 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
NZ542988A (en) * 2003-04-23 2008-07-31 Medarex Inc Humanised antibodies directed against the IFNAR-1 receptor in which murine CDR sequences have been grafted directly into unmodified human framework sequences, resulting in high affinity, functional antibodies
JP4599355B2 (ja) 2003-07-28 2010-12-15 ジェネンテック, インコーポレイテッド プロテインaアフィニティークロマトグラフィーの間のプロテインaの浸出の低減
EP2168986A3 (en) 2004-02-19 2010-07-28 Genentech, Inc. CDR-repaired antibodies
CA2554965C (en) * 2004-02-19 2015-08-11 The Cbr Institute For Biomedical Research, Inc. Antibodies specific for activated conformation of lfa-1
EP1756163A2 (en) * 2004-06-09 2007-02-28 Genentech, Inc. Method of treating granuloma annulare or sarcoid
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8163886B2 (en) 2006-12-21 2012-04-24 Emd Millipore Corporation Purification of proteins
RU2474585C2 (ru) 2007-01-22 2013-02-10 Дженентек, Инк. Осаждение и очистка белков полиэлектролитами
EP2586788B1 (en) 2007-07-09 2017-11-29 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
HUE024877T2 (en) 2007-10-30 2016-02-29 Genentech Inc Antibody purification by cation exchange chromatography
WO2009126688A2 (en) * 2008-04-09 2009-10-15 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
EP2145901B1 (en) 2008-07-18 2012-11-14 Technische Universität Braunschweig Recombinant anti-MUC1 antibodies
HUE066562T2 (hu) 2008-08-14 2024-08-28 Genentech Inc Eljárások szennyezés eltávolítására indigén fehérje kiszorításos ioncserés membrán kromatográfia alkalmazásával
EP2684570A1 (en) 2008-09-10 2014-01-15 F. Hoffmann-La Roche AG Compositions and methods for the prevention of oxidative degradation of proteins
DK2370561T3 (da) 2008-12-16 2019-10-21 Emd Millipore Corp Omrøringstankreaktor og fremgangsmåde
US20110020327A1 (en) 2008-12-16 2011-01-27 Millipore Corporation Purification of proteins
US8435488B2 (en) 2009-02-27 2013-05-07 Genentech, Inc. Methods and compositions for protein labelling
MX355650B (es) 2009-08-11 2018-04-26 Genentech Inc Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
BR112012004697B8 (pt) 2009-09-01 2021-05-25 Genentech Inc método para purificar um polipeptídeo compreendendo uma região ch2/ch3
WO2011060135A1 (en) 2009-11-12 2011-05-19 Vbi Technologies, Llc Subpopulations of spore-like cells and uses thereof
WO2011095596A1 (en) 2010-02-04 2011-08-11 Vivalis Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
KR101878369B1 (ko) 2010-03-22 2018-07-16 제넨테크, 인크. 단백질-함유 제제의 안정화에 유용한 조성물 및 방법
BR112012027828A2 (pt) 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
CN102892791B (zh) 2010-05-17 2017-05-17 Emd密理博公司 用于纯化生物分子的刺激响应性聚合物
JP6050226B2 (ja) 2010-05-28 2016-12-21 ジェネンテック, インコーポレイテッド Ldh及びpdhk発現を下方制御することによる乳酸レベルの低下及びポリペプチド生産の増加
KR101924653B1 (ko) 2010-06-24 2018-12-03 제넨테크, 인크. 단백질-함유 제제를 안정화시키기 위한 알킬글리코시드 함유 조성물 및 방법
CN104474546A (zh) 2010-08-13 2015-04-01 弗·哈夫曼-拉罗切有限公司 用于疾病治疗的针对IL-1β和IL-18的抗体
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
WO2012088272A1 (en) * 2010-12-21 2012-06-28 Duke University Methods and compositions combining immunotherapy with monocyte activation
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
PL2794635T3 (pl) 2011-12-22 2019-02-28 F.Hoffmann-La Roche Ag Membranowa chromatografia jonowymienna
SG11201406112TA (en) 2012-03-27 2014-10-30 Genentech Inc Improved harvest operations for recombinant proteins
SI2849723T1 (sl) 2012-05-18 2018-09-28 Genentech, Inc. Formulacije z visoko koncentracijo monoklonskih protiteles
WO2014100095A1 (en) 2012-12-19 2014-06-26 Genentech, Inc. Methods and compositions for radiohalogen protein labeling
SG11201510316UA (en) 2013-07-09 2016-01-28 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
TWI888366B (zh) 2013-07-16 2025-07-01 美商建南德克公司 利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法
CN106686977B (zh) 2014-07-09 2022-03-25 豪夫迈·罗氏有限公司 Ph调整以改善细胞库的解冻复苏
PL3215527T3 (pl) 2014-11-05 2025-04-28 Annexon, Inc. Humanizowane przeciwciała przeciwko czynnikowi dopełniacza C1Q i ich zastosowanie
US10946095B2 (en) 2015-09-02 2021-03-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT)
SG10202007764TA (en) 2015-09-25 2020-09-29 Genentech Inc Anti-tigit antibodies and methods of use
FI3380518T3 (fi) 2015-11-24 2026-05-29 Annexon Inc Antikomplementtitekijä-C1Q:n Fab-fragmentteja ja niiden käyttöjä
JP2019510517A (ja) 2016-03-29 2019-04-18 ジェルター, インコーポレイテッド 細胞質内体積に対するペリプラズム体積の比率が0.5:1および10:1の間にあるグラム陰性細菌におけるタンパク質の発現
AU2017382281B2 (en) 2016-12-22 2024-07-11 Genentech, Inc. Methods and formulations for reducing reconstitution time of lyophilized polypeptides
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
IL279782B2 (en) 2018-07-03 2026-05-01 Bristol Myers Squibb Co Methods for producing recombinant proteins
KR20210074341A (ko) 2018-10-10 2021-06-21 베링거 인겔하임 인터내셔날 게엠베하 고밀도 생물 반응기 배양에서 막 기체 전달을 위한 방법
WO2020205716A1 (en) 2019-04-01 2020-10-08 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
GB2597416A (en) 2019-04-12 2022-01-26 Geltor Inc Recombinant elastin and production thereof
US20220315887A1 (en) 2019-08-01 2022-10-06 Bristol-Myers Squibb Company Methods of improving protein productivity in fed-batch cell cultures
CN116194570A (zh) 2020-09-22 2023-05-30 百时美施贵宝公司 用于产生治疗性蛋白的方法
US20250115666A1 (en) 2021-08-05 2025-04-10 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
US20240390869A1 (en) 2021-09-21 2024-11-28 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
US12486322B2 (en) 2021-12-13 2025-12-02 Annexon, Inc. Anti-complement factor C1q antibodies with single binding arms and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ236792A (en) * 1990-01-19 1993-05-26 Merck & Co Inc Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions
US6096871A (en) * 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life

Also Published As

Publication number Publication date
WO1998023761A1 (en) 1998-06-04
EP0941344B1 (en) 2004-05-19
DE69729209T2 (de) 2005-05-19
CA2272842A1 (en) 1998-06-04
ZA979599B (en) 1999-04-28
DE122004000047I1 (de) 2005-04-21
FR04C0028I2 (cg-RX-API-DMAC10.html) 2007-10-26
JP4309383B2 (ja) 2009-08-05
NL300163I2 (nl) 2005-07-01
ES2221045T3 (es) 2004-12-16
CA2272842C (en) 2012-05-15
EP1516629B1 (en) 2013-04-03
AU4992997A (en) 1998-06-22
DK0941344T3 (da) 2004-09-27
IL175583A0 (en) 2006-09-05
AU731817C (en) 2001-11-01
PT941344E (pt) 2004-10-29
EP0941344A1 (en) 1999-09-15
ATE267257T1 (de) 2004-06-15
KR20000069147A (ko) 2000-11-25
IL130143A (en) 2006-08-01
AU731817B2 (en) 2001-04-05
DK1516629T3 (da) 2013-06-03
IL130143A0 (en) 2000-06-01
EP1516629A2 (en) 2005-03-23
DE69729209D1 (de) 2004-06-24
FR04C0028I1 (cg-RX-API-DMAC10.html) 2005-02-11
JP3778945B2 (ja) 2006-05-24
DE122004000047I2 (de) 2006-06-14
AR008919A1 (es) 2000-02-23
JP2001505425A (ja) 2001-04-24
JP2006036779A (ja) 2006-02-09
NL300163I1 (nl) 2005-01-03
LU91122I2 (fr) 2005-01-10
EP1516629A3 (en) 2006-09-27

Similar Documents

Publication Publication Date Title
JP4309383B2 (ja) ヒト化抗CD11a抗体
US6703018B2 (en) Method of treatment using humanized anti-CD11a antibodies
US11485782B2 (en) Anti-claudin 18.2 antibodies
CN101360826B (zh) 抗α2整联蛋白抗体及它们的用途
WO2021047599A1 (en) Humanized anti-claudin 18.2 (cldn18.2) antibodies
US20080241126A1 (en) Nucleic acids encoding Human Engineered heavy and light chain variable region sequences to Ep-CAM
KR20010014422A (ko) 개선된 항-IgE 항체 및 폴리펩티드의 개선 방법
JP2001509817A (ja) 抗vegf抗体
JP2004000249A (ja) 抗体の調製
JP6998309B2 (ja) 抗ポドカリキシン抗体及びその使用方法
EP1708961B1 (en) Anti-ip-10 antibodies
EP0946727B1 (en) Antibody mutants
US20040146507A1 (en) Antibody mutants
MXPA99004795A (en) HUMANIZED ANTI-CD11a ANTIBODIES
KR20000075545A (ko) 감마-1 및 감마-3 항사람 cd23 단클론성 항체 및 치료제로서이들을 사용하는 방법
MXPA99007688A (en) Gamma-1 and gamma-3 anti-human cd23 monoclonal antibodies and use thereof as therapeutics

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19990527

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20021019

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20041126

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20050601

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20041126

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20050627

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20050601

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20050826

Appeal identifier: 2005101004140

Request date: 20050627

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20050627

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20050627

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20050426

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20021019

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20050826

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20050728

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20051123

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20051124

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20081110

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20091110

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20101122

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20111101

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20121031

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20121031

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20131030

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20131030

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20141030

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20141030

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20150930

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20150930

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20161028

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20161028

Start annual number: 12

End annual number: 12

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20180420

Termination category: Expiration of duration